Cash Flow Statement

Amortization Amortization Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Ratios

ProQR Therapeutics (PRQR) Capital Expenditures (2016 - 2022)

ProQR Therapeutics' Capital Expenditures history spans 2 years, with the latest figure at $1.5 million for Q4 2022.

On a quarterly basis, Capital Expenditures rose 666.42% to $1.5 million in Q4 2022 year-over-year; TTM through Dec 2022 was $689557.5, a 222.05% increase, with the full-year FY2025 number at $1.2 million, down 21.64% from a year prior.
Capital Expenditures hit $1.5 million in Q4 2022 for ProQR Therapeutics, up from -$248035.5 in the prior quarter.
Over the last five years, Capital Expenditures for PRQR hit a ceiling of $1.5 million in Q4 2022 and a floor of -$273850.4 in Q1 2022.